CalciMedica, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
CalciMedica completed a private placement financing of approximately $49M (with ~$15M upfront) on June 24, 2026, to advance its pulmonary hypertension program including Auxora Phase 1b trial in PAH and CM5480 IND submission, both anticipated mid-2027. The company also achieved FDA alignment on Phase 2b acute pancreatitis trial design (primary endpoint: reduction in new-onset severe respiratory failure). Cash position: $18.6M as of June 30, 2026; net loss H1 2026: $2.7M ($0.16/share); common shares outstanding increased to 30.7M from 15.4M (99% dilution from capital raise).
Why this rating
Large financing (~3.1× current market cap) extends runway to H2 2027, enables two material clinical catalysts, and validates strategy. Significant relative to $15.7M market cap; positive regulatory alignment.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.